• Zinc / Zinc Ionophore approach inhibits RNA dependent RNA polymerase (RDRP)
• RDRP is essential for some RNA viruses such as:
• all the Coronavirus strains • all the influenza strains • RSV
Zinc Ionophores include:
• Hydroxychloroquine • Ivermectin • Quercetin • EGCG
We can potentially cure all Corona, Influenza, and RSV infections with a safe, cheap, and oral treatment approach.
This is why the Globalists, Pharmaceutical industry, tyrants, despots, and devolved pagans are opposing this approach...
It undermines their agenda, profits, and the use of fear as a weapon.
We must resist and sacrifice at all costs and win the war for God-consciousness and freedom from tyranny.
Vladimir Zev Zelenko MD https://gettr.com/post/p8bu2oa250
This is what I am seeing this morning. All the so called vaccines at best only target one strain. Meanwhile actual therapeutics are broad spectrum and can wipe out all variants. Why would anyone get a feeble vaccine instead of broad spectrum protection???
https://www.thedesertreview.com/opinion/columnists/indias-ivermectin-blackout/article_e3db8f46-f942-11eb-9eea-77d5e2519364.html
Ionophores and Quercetin https://gilbertlab.com/neutraceuticals/quercetin/antiviral-effects-of-quercetin-zinc-ionophore/
Just a quick reminder that Ivermectin won the Nobel Prize for Medicine in 2015, has been used safely in tropical countries since 1981, is consumed regularly by tens of millions of people, and has saved millions from river blindness, elephantiasis, and other parasite-born diseases.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043740/
With thanks to the Anons who posted these links originally.
Yours is a very key point. Each year a cold/flu vaccine is targeted and developed. It is not at all unusual for it to miss the mark and essentially be ineffective. In that case those affected generally overcome(kill) the virus with their own "natural" immune response. Then next "year" the dice are thrown again. Maybe it's time the insurance companies, who generally pay for all of this, wake up to the viability of cheap therapeutics.